drugset

drugset / Trial / NCT06547528

A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

NCT06547528 ↗

Phase 1 Recruiting 108 enrolled Ono Pharmaceutical Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

A Phase I Study to Investigate the Tolerability and Safety of ONO-4685 Given as Monotherapy in T Cell Lymphoma and CLL/SLL

Timeline

Start: 2023-10-01
Primary completion: 2029-01-31
Completion: 2029-04-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ONO-4685	Unknown	—	Intravenous

Indications